Quan Dong Nguyen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5279168/publications.pdf

Version: 2024-02-01

		109137	3	32761	
132	10,663	35		100	
papers	citations	h-index		g-index	
166	166	166		6187	
all docs	docs citations	times ranked		citing authors	

#	Article	IF	CITATIONS
1	Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology, 2012, 119, 2537-2548.	2.5	1,947
2	Ranibizumab for Diabetic Macular Edema. Ophthalmology, 2012, 119, 789-801.	2.5	1,392
3	Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials. Ophthalmology, 2013, 120, 2013-2022.	2.5	728
4	Intravitreal Aflibercept for Diabetic Macular Edema. Ophthalmology, 2014, 121, 2247-2254.	2.5	668
5	Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology, 2010, 117, 2146-2151.	2.5	485
6	Adalimumab in Patients with Active Noninfectious Uveitis. New England Journal of Medicine, 2016, 375, 932-943.	13.9	470
7	Intravitreal Aflibercept for Diabetic MacularÂEdema. Ophthalmology, 2015, 122, 2044-2052.	2.5	451
8	Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet, The, 2016, 388, 1183-1192.	6.3	387
9	Vascular Endothelial Growth Factor Is a Critical Stimulus for Diabetic Macular Edema. American Journal of Ophthalmology, 2006, 142, 961-969.e4.	1.7	332
10	Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology, 2009, 116, 2175-2181.e1.	2. 5	318
11	Mycophenolate Mofetil Therapy for Inflammatory Eye Disease. Ophthalmology, 2005, 112, 1472-1477.	2.5	207
12	Supplemental Oxygen Improves Diabetic Macular Edema: A Pilot Study. , 2004, 45, 617.		174
13	Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 963-976.	2.5	143
14	A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular Degeneration. Ophthalmology, 2006, 113, 1522.e1-1522.e14.	2.5	141
15	Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Ophthalmology, 2018, 125, 1075-1087.	2.5	134
16	Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy. Ophthalmology, 2015, 122, 2504-2513.e1.	2.5	127
17	Endogenous endophthalmitis: diagnosis, management, and prognosis. Journal of Ophthalmic Inflammation and Infection, 2015, 5, 32.	1,2	125
18	Aqueous Levels of Fluocinolone Acetonide after Administration of Fluocinolone Acetonide Inserts or Fluocinolone Acetonide Implants. Ophthalmology, 2013, 120, 583-587.	2.5	119

#	Article	IF	CITATIONS
19	Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis. American Journal of Ophthalmology, 2017, 183, 71-80.	1.7	118
20	Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion. Ophthalmology, 2015, 122, 1426-1437.	2.5	98
21	Dose-Ranging Evaluation of Intravitreal siRNA PF-04523655 for Diabetic Macular Edema (the DEGAS) Tj ETQq1 1	0.784314	4 rgBT /Ove
22	A Cross-sectional Study of the Current Treatment Patterns in Noninfectious Uveitis among Specialists in the United States. Ophthalmology, 2011, 118, 184-190.	2.5	87
23	Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. Journal of Ophthalmic Inflammation and Infection, 2013, 3, 32.	1.2	84
24	Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. American Journal of Ophthalmology Case Reports, 2020, 18, 100687.	0.4	79
25	Treating Chronic Noninfectious Posterior Segment Uveitis. Retina, 2006, 26, 1-16.	1.0	77
26	Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA). Ophthalmology, 2016, 123, 2413-2423.	2.5	73
27	Suprachoroidal Corticosteroid Administration: A Novel Route for Local Treatment of Noninfectious Uveitis. Translational Vision Science and Technology, 2016, 5, 14.	1.1	65
28	Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmologica, 2018, 96, e1-e9.	0.6	60
29	Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy. Diabetes Care, 2021, 44, 748-756.	4.3	59
30	Pharmacotherapy for uveitis: current management and emerging therapy. Clinical Ophthalmology, 2014, 8, 1891.	0.9	53
31	Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU):. Ophthalmology, 2019, 126, 428-437.	2.5	49
32	Effect of Vitreomacular Adhesion on Treatment Outcomes in the Ranibizumab for Edema of the Macula in Diabetes (READ-3) Study. Ophthalmology, 2016, 123, 324-329.	2.5	48
33	One-Year Outcomes of the SAVE Study: <u>S</u> irolimus as a Therapeutic <u>A</u> pproach for U <u>VE</u> itis. Translational Vision Science and Technology, 2015, 4, 4.	1.1	47
34	Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitisâ€"Report 2. Ophthalmology, 2021, 128, 277-287.	2.5	46
35	Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitisâ€"Report 1. Ophthalmology, 2021, 128, 266-276.	2.5	46
36	The Relationship Between Macular Sensitivity and Retinal Thickness in Eyes With Diabetic Macular Edema. American Journal of Ophthalmology, 2011, 152, 400-405.e2.	1.7	40

#	Article	IF	CITATIONS
37	New therapies in development for the management of nonâ€infectious uveitis: A review. Clinical and Experimental Ophthalmology, 2019, 47, 396-417.	1.3	38
38	PHARMACOKINETIC STUDY OF INTRAVITREAL AFLIBERCEPT IN HUMANS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2020, 40, 643-647.	1.0	38
39	THE COLLABORATIVE OCULAR TUBERCULOSIS STUDY (COTS)-1. Retina, 2019, 39, 1623-1630.	1.0	37
40	Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti–Vascular Endothelial Growth Factor Treatment. Ophthalmology, 2016, 123, 850-857.	2.5	35
41	High-Resolution Imaging of Parafoveal Cones in Different Stages of Diabetic Retinopathy Using Adaptive Optics Fundus Camera. PLoS ONE, 2016, 11, e0152788.	1.1	32
42	Fundus autofluorescence imaging: Fundamentals and clinical relevance. Saudi Journal of Ophthalmology, 2014, 28, 111-116.	0.3	30
43	Evaluation of macular and peripapillary vessel flow density in eyes with no known pathology using optical coherence tomography angiography. International Journal of Retina and Vitreous, 2017, 3, 27.	0.9	29
44	Diurnal variation of choriocapillaris vessel flow density in normal subjects measured using optical coherence tomography angiography. International Journal of Retina and Vitreous, 2018, 4, 37.	0.9	29
45	Intravenous Bevacizumab Causes Regression of Choroidal Neovascularization Secondary to Diseases Other Than Age-related Macular Degeneration. American Journal of Ophthalmology, 2008, 145, 257-266.e2.	1.7	28
46	Heterochromatin protects retinal pigment epithelium cells from oxidative damage by silencing p53 target genes. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3987-E3995.	3 . 3	27
47	Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis. Ophthalmology, 2018, 125, 1984-1993.	2.5	27
48	The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. International Journal of Retina and Vitreous, 2020, 6, 48.	0.9	27
49	Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema. World Journal of Diabetes, 2013, 4, 303.	1.3	26
50	Platelet derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization. Saudi Journal of Ophthalmology, 2015, 29, 287-291.	0.3	25
51	Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology, 2021, 128, 899-909.	2.5	25
52	Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment. Ophthalmology, 2020, 127, 1405-1415.	2.5	23
53	Emerging Therapies for Noninfectious Uveitis: What May Be Coming to the Clinics. Journal of Ophthalmology, 2014, 2014, 1-7.	0.6	22
54	Comparison of short-pulse subthreshold (532Ânm) and infrared micropulse (810Ânm) macular laser for diabetic macular edema. Scientific Reports, 2021, 11, 14.	1.6	22

#	Article	IF	CITATIONS
55	Assessment of Central Retinal Sensitivity Employing Two Types of Microperimetry Devices. Translational Vision Science and Technology, 2014, 3, 3.	1.1	21
56	Assessment of changes in quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis. Journal of Ophthalmic Inflammation and Infection, 2015, 5, 13.	1.2	21
57	Management of macular edema due to central retinal vein occlusion – The role of aflibercept. Taiwan Journal of Ophthalmology, 2017, 7, 70.	0.3	21
58	Subcutaneous repository corticotropin gel for non-infectious panuveitis: Reappraisal of an old pharmacologic agent. American Journal of Ophthalmology Case Reports, 2016, 4, 78-82.	0.4	19
59	Updates on the clinical trials in diabetic macular edema. Middle East African Journal of Ophthalmology, 2016, 23, 3.	0.5	19
60	The Effect of Different Dosing Schedules of Intravitreal Sirolimus, a Mammalian Target of Rapamycin (mTOR) Inhibitor, in the Treatment of Non-Infectious Uveitis (An American Ophthalmological Society) Tj ETQq0	0 0 1 g/BT /0	Overbock 10 T
61	Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?. Expert Opinion on Biological Therapy, 2022, 22, 1275-1291.	1.4	18
62	Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases. Biologics in Therapy, 2012, 2, 3.	1.8	17
63	Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials. Ocular Immunology and Inflammation, 2019, 27, 40-50.	1.0	17
64	Recent advances in the management and understanding of diabetic retinopathy. F1000Research, 2017, 6, 2063.	0.8	17
65	Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics. Pharmacogenomics and Personalized Medicine, 2014, 7, 399.	0.4	16
66	Combined systemic and ocular chemotherapy for anterior segment metastasis of systemic mantle cell lymphoma. Journal of Ophthalmic Inflammation and Infection, 2015, 5, 30.	1.2	16
67	Characterization of retinal structure and diagnosis of peripheral acquired retinoschisis using high-resolution ultrasound B-scan. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 69-75.	1.0	16
68	Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic. British Journal of Ophthalmology, 2021, 105, 639-647.	2.1	16
69	Variation of choroidal thickness and vessel diameter in patients with posterior non-infectious uveitis. Journal of Ophthalmic Inflammation and Infection, 2014, 4, 14.	1.2	14
70	Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema. International Journal of Retina and Vitreous, 2019, 5, 28.	0.9	14
71	Sirolimus for Retinal and Uveitic Diseases. Developments in Ophthalmology, 2016, 55, 276-281.	0.1	13
72	Bilateral papillitis and unilateral focal chorioretinitis as the presenting features of syphilis. Journal of Ophthalmic Inflammation and Infection, 2015, 5, 16.	1.2	13

#	Article	IF	CITATIONS
73	Adaptive Optics Imaging of Retinal Photoreceptors Overlying Lesions in White Dot Syndrome and its Functional Correlation. American Journal of Ophthalmology, 2015, 160, 806-816.e2.	1.7	13
74	Retinal sensitivity is a valuable complementary measurement to visual acuity — a microperimetry study in patients with maculopathies. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 2137-2142.	1.0	13
75	Fixation Stability Measurement Using Two Types of Microperimetry Devices. Translational Vision Science and Technology, 2015, 4, 3.	1.1	11
76	lmaging in Tubercular Choroiditis: Current Concepts. Ocular Immunology and Inflammation, 2020, 28, 1223-1238.	1.0	11
77	Proteomic analysis of intermediate uveitis suggests myeloid cell recruitment and implicates IL-23 as a therapeutic target. American Journal of Ophthalmology Case Reports, 2020, 18, 100646.	0.4	11
78	The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy. Pharmacogenomics, 2016, 17, 309-320.	0.6	10
79	A fatal case of Susac syndrome: The importance of ophthalmic examination in confirming the diagnosis. American Journal of Ophthalmology Case Reports, 2018, 12, 18-20.	0.4	10
80	Amine oxidase copper-containing 3 (AOC3) inhibition: a potential novel target for the management of diabetic retinopathy. International Journal of Retina and Vitreous, 2021, 7, 30.	0.9	9
81	High-resolution adaptive optics findings in talc retinopathy. International Journal of Retina and Vitreous, 2015, 1, 10.	0.9	8
82	Safety of systemic therapy for noninfectious uveitis. Expert Opinion on Drug Safety, 2019, 18, 1219-1235.	1.0	8
83	Posterior segment inflammatory outcomes assessed using fluorescein angiography in the STOP-UVEITIS study. International Journal of Retina and Vitreous, 2020, 6, 47.	0.9	8
84	The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting Proceedings. Ocular Immunology and Inflammation, 2020, , 1-11.	1.0	8
85	Lessons in Digital Epidemiology from COTS-1: Coordinating Multicentre Research across 10 Countries Using Operational and Technology Innovation to Overcome Funding Deficiencies. Ocular Immunology and Inflammation, 2020, , 1-7.	1.0	8
86	The transcription factor CREB acts as an important regulator mediating oxidative stress-induced apoptosis by suppressing $\hat{l}_{\pm}B$ -crystallin expression. Aging, 2020, 12, 13594-13617.	1.4	8
87	The role of Aflibercept in the management of age-related macular degeneration. Expert Opinion on Biological Therapy, 2016, 16, 699-709.	1.4	7
88	Correlation of Vitreomacular Traction with Foveal Thickness, Subfoveal Choroidal Thickness, and Vitreomacular/Foveal Angle. Current Eye Research, 2017, 42, 297-301.	0.7	7
89	Obtaining undiluted vitreous sample using small gauge pars plana vitrectomy and air infusion. American Journal of Ophthalmology Case Reports, 2020, 19, 100768.	0.4	7
90	Reperfusion of retinal ischemia in retinal occlusive vasculitis with nicotinic acid and infliximab in Adamantiades-Behçet's disease. American Journal of Ophthalmology Case Reports, 2021, 21, 101027.	0.4	7

#	Article	IF	CITATIONS
91	Tocilizumab for the Treatment of Ocular Inflammatory Disease. Ocular Immunology and Inflammation, 2021, 29, 2-5.	1.0	7
92	Assessment of oxygen saturation in retinal vessels of normal subjects and diabetic patients with and without retinopathy using Flow Oximetry System. Quantitative Imaging in Medicine and Surgery, 2015, 5, 86-96.	1.1	7
93	The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Review of 447 Patients with Tubercular Intermediate Uveitis and Panuveitis. Ocular Immunology and Inflammation, 2020, 28, 27-37.	1.0	6
94	Management of repository corticotropin injection therapy for nonâ€infectious uveitis: a Delphi study. Acta Ophthalmologica, 2021, 99, 669-678.	0.6	6
95	Effect of vitreomacular adhesion on the treatment outcomes in the STOP-Uveitis clinical trial for non-infectious uveitis. Journal of Ophthalmic Inflammation and Infection, 2019, 9, 12.	1.2	5
96	The small heat shock protein $\hat{l}\pm A$ -crystallin negatively regulates pancreatic tumorigenesis. Oncotarget, 2016, 7, 65808-65824.	0.8	5
97	Correlation of Clinical Aqueous Flare Grading to Semi-Automated Flare Measurements Using Laser Flare Photometry. Ocular Immunology and Inflammation, 2022, 30, 1906-1912.	1.0	5
98	The Collaborative Ocular Tuberculosis Study (COTS) calculator—a consensus-based decision tool for initiating antitubercular therapy in ocular tuberculosis. Eye, 2023, 37, 1416-1423.	1.1	5
99	Correlation between Subfoveal Choroidal Thickness and Anterior Segment Inflammation in Patients with Chronic Stage of Vogt-Koyanagi-Harada Disease. Ocular Immunology and Inflammation, 2022, 30, 646-651.	1.0	4
100	Yet another case of ocular sarcoidosis. American Journal of Ophthalmology Case Reports, 2020, 19, 100825.	0.4	4
101	Bilateral preretinal hemorrhage associated with Kikuchi-Fujimoto disease. American Journal of Ophthalmology Case Reports, 2021, 22, 101041.	0.4	4
102	Voclosporin: a potentially promising therapeutic agent for noninfectious uveitis. Expert Review of Ophthalmology, 2011, 6, 281-286.	0.3	3
103	Author reply. Ophthalmology, 2014, 121, e5-e6.	2.5	3
104	Reliability and reproducibility of spectral and time domain optical coherence tomography images before and after correction for patients with age-related macular degeneration. F1000Research, 2013, 2, 131.	0.8	3
105	Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin. Kidney International Reports, 2022, 7, 763-775.	0.4	3
106	Utilisation of composite endpoint outcome to assess efficacy of tocilizumab for non-infectious uveitis in the STOP-Uveitis Study. British Journal of Ophthalmology, 2023, 107, 1197-1201.	2.1	3
107	Ocular complications of HIV/AIDS in the era of HAART. Expert Review of Ophthalmology, 2012, 7, 555-564.	0.3	2
108	Nonbiological pharmacotherapies for the treatment of diabetic macular edema. Expert Opinion on Pharmacotherapy, 2015, 16, 2625-2635.	0.9	2

#	Article	IF	CITATIONS
109	Assessment of retinal vessel caliber changes in eyes with non-neovascular age-related macular degeneration after progression to neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 599-601.	1.0	2
110	Adult body height and age-related macular degeneration in healthy individuals: A nationwide population-based survey from Korea. PLoS ONE, 2020, 15, e0232593.	1.1	2
111	Distinct Patterns of Choroidal Lesions in Punctate Inner Choroidopathy and Multifocal Choroiditis Determined by Heatmap Analysis. Ocular Immunology and Inflammation, 2021, , 1-6.	1.0	2
112	Serous retinal detachment as a presenting sign of acute lymphoblastic leukemia: A case report and literature review. American Journal of Ophthalmology Case Reports, 2021, 23, 101142.	0.4	2
113	Multifocal choroiditis with retinal vasculitis, optic neuropathy, and keratoconus in a young Saudi male. Middle East African Journal of Ophthalmology, 2017, 24, 109.	0.5	2
114	The Historical Evolution of Ocular Tuberculosis: Past, Present, and Future. Ocular Immunology and Inflammation, 2021, , 1-7.	1.0	2
115	Omics Technologies and Neovascular Ocular Disorders. BioMed Research International, 2014, 2014, 1-2.	0.9	1
116	Update on Uveitis Management. Journal of Ophthalmology, 2015, 2015, 1-1.	0.6	1
117	MO002OPHTHALMOLOGICAL EFFECTS OF ROXADUSTAT IN THE TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISEASE PATIENTS ON DIALYSIS IN A PHASE 3, RANDOMISED, DOUBLE-BLIND, ACTIVE-COMPARATOR CONVERSION STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	1
118	CRB1-associated retinal dystrophy presenting as self-resolving opsoclonus and posterior uveitis. American Journal of Ophthalmology Case Reports, 2022, 26, 101444.	0.4	1
119	Systemic and Intraocular Methotrexate for the Prevention and Treatment of Proliferative Vitreoretinopathy in Children With Rhegmatogenous Retinal Detachment and Underlying Inflammatory Disease. Journal of Vitreoretinal Diseases, 0, , 247412642210763.	0.2	1
120	Putting Theories and Results into Practice. Ophthalmology, 2013, 120, S16-S22.	2.5	0
121	Computerâ€aided analysis of fluorescein angiograms using colour leakage maps. IET Image Processing, 2015, 9, 486-495.	1.4	O
122	Reply. Ophthalmology, 2016, 123, e33-e34.	2.5	0
123	Advances in imaging and molecular diagnostics of ocular tuberculosis and selected observations from the Collaborative Ocular Tuberculosis Study (COTS). Expert Review of Ophthalmology, 2018, 13, 361-371.	0.3	O
124	Advanced Birdshot Chorioretinopathy Presenting as Chronic Cystoid Macular Edema and Vitritis Following Cataract Surgery. Journal of Vitreoretinal Diseases, 2019, 3, 49-53.	0.2	0
125	Reply. Ophthalmology, 2020, 127, e102-e103.	2.5	O
126	Reply. Retina, 2020, 40, e13-e14.	1.0	0

#	Article	IF	CITATIONS
127	Reply. Ophthalmology, 2021, 128, e35-e36.	2.5	O
128	Reply. Ophthalmology, 2021, 128, e218-e219.	2.5	0
129	Novel surgical approach for removing intraretinal loculated foveal hemorrhage in a patient with hypertensive retinopathy. American Journal of Ophthalmology Case Reports, 2021, 24, 101217.	0.4	O
130	How Do We Manage HLA-B27-associated Ocular Inflammation Refractory or Intolerant to Conventional Immunomodulatory Therapy?. Journal of Ophthalmic and Vision Research, 2020, 15, 442-445.	0.7	0
131	Telemedicine screening for syphilitic chorioretinitis in the SUNDROP cohort. Eye, 2022, , .	1.1	0
132	Reflectance adaptive optics findings in a patient with Vogt-Koyanagi-Harada disease. American Journal of Ophthalmology Case Reports, 2022, 27, 101660.	0.4	0